3SOF

We've been watching this one as well... their CPP-109 clinical data slated to be presented on April 16th during the American Society of Addiction Medicine meeting. Investors were hoping that it would be new data, but recent news has dampened those hopes.

From an AP report today:

"Catalyst said the National Institute on Drug Abuse will cover most of the costs of a new midstage clinical trial of CPP-109, which is also called vigabatrin. The drug intended to help break addiction, but clinical trials involving cocaine and methamphetamine addicts have not been successful."

However, the company noted:

"According to Catalyst, the last trial of vigabatrin in cocaine addiction failed because not enough patients took the drug. The company said an independent panel agreed there was enough evidence the drug helped patients stay off cocaine. Vigabatrin's effectiveness against methamphetamine was not much different from a placebo, although Catalyst said that result was also encouraging."

Nevertheless, April 16th could be a day to watch this one.

We have been following this company closely lately.

From our recent coverage:

"Earlier this month, a committee of shareholders calling themselves the Ad Hoc Equity Committee submitted a letter seeking fair treatment during the Chapter 11 proceedings. The shareholders believe that the court's valuation is inconsistent with the company's strong top-line and bottom-line growth in recent months, particularly after cost-cutting measures."

Here's the letter we referenced directly from the SEC:
http://edgar.sec.gov/Archives/edgar/data/928549/000095012310028311/k48960aexv99w4.htm

China Linen Textile Industry Ltd. (CTXIF.OB) is a fundamentally strong and profitable OTC-BB stock that we featured today on Sumfolio (link below).

Company Profile

China Linen Textile Industry Ltd. ("CTXIF" or the "Company") is a leading China-based manufacturer and distributor of linen products. The Company manufactures over 50 types of linen yarn and 100 varieties of linen fabric and products. Roughly 55% of CTXIF's production is exported to Europe, North America, the Middle East and South America with the remainder sold in China. The Company enjoys a 5% market share of China's total linen industry and ranks among the top 5 companies in China's linen textile industry. CTXIF has posted annual revenue and net profit growth of about 40% on average for the last five years. The Company is running its plants at peak utilization and still requires outsourced production to meet excess demand. With capacity additions expected in the next few years, we are projecting 20% year-over-year growth in the short-term and 15% year-over-year growth in the mid-term.

Investment Highlights

• Net Income of $0.30/Share in 2009
• Projected Net Income of $0.46/Share in 2010
• 42% 5yr CAGR for Revenues and 44% 5yr CAGR for Net Income
• Forward P/E of Less than 4x and PEG of Less than 0.5

Link to Our Analysis

Here's a link to our article on the company:
http://sumfolio.com/capitalize-on-chinas-textile-industry-with-cxtif-416/